Download the Complete Report Here
Key Takeaways:
International medical cannabis revenue increased 17% to C$43.3 million in 1Q FY27, reinforcing ACB's leadership across global medical markets.
Adjusted gross margin reached 58%, the high end of FY27 guidance, despite the full initial impact of the ~30% Canadian reimbursement cut.
Safari contributed positively to adjusted EBITDA in its first quarter, while three-year EU-GMP certification expands internal supply for high-margin international markets.
#markets
Key Takeaways:
International medical cannabis revenue increased 17% to C$43.3 million in 1Q FY27, reinforcing ACB's leadership across global medical markets.
Adjusted gross margin reached 58%, the high end of FY27 guidance, despite the full initial impact of the ~30% Canadian reimbursement cut.
Safari contributed positively to adjusted EBITDA in its first quarter, while three-year EU-GMP certification expands internal supply for high-margin international markets.
#markets
2 months ago
